Inozyme Pharma Inc. (INZY)
0.92
-0.04 (-4.35%)
At close: Apr 17, 2025, 3:59 PM
0.94
2.38%
After-hours: Apr 17, 2025, 07:55 PM EDT
-4.35% (1D)
| Bid | 0.9 |
| Market Cap | 59.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.02M |
| EPS (ttm) | -1.62 |
| PE Ratio (ttm) | -0.57 |
| Forward PE | -0.73 |
| Analyst | Buy |
| Ask | 0.98 |
| Volume | 305,187 |
| Avg. Volume (20D) | 593,416 |
| Open | 0.98 |
| Previous Close | 0.96 |
| Day's Range | 0.91 - 0.99 |
| 52-Week Range | 0.72 - 6.24 |
| Beta | 1.39 |
About INZY
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for spec...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 67
Stock Exchange NASDAQ
Ticker Symbol INZY
Website https://www.inozyme.com
Analyst Forecast
According to 8 analyst ratings, the average rating for INZY stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 1585.70% from the latest price.
Stock Forecasts3 months ago
-14%
Inozyme Pharma shares are trading lower after mult...
Unlock content with
Pro Subscription
